// App-Quantinova.ai

1412 : Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study

Researchers

Presenter

  • Janet Pope

Principal Investigators

  • Boulos Haraoui

  • Eduardo Mysler

  • Annette Diehl

  • Tatjana Lukic

  • Shixue Liu

  • Lori Stockert

  • Sujatha Menon

  • Edward Keystone

Medical Centers

  • Metroplex Clinical Research Center, Dallas, TX,

  • Western Univeristy, London, ON, Canada

  • Institut de Rhumatologie, Montreal, QC, Canada

  • Organizacion Medica de Investigacion, Buenos Aires, Argentina

  • Pfizer Inc, Collegeville, PA

  • Pfizer Inc, New York, NY

  • Pfizer Inc, Shanghai, China (People's Republic)

  • Pfizer, Groton, CT

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

Locations

  • United States

  • Canada

  • Argentina

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved